|
|
| This yearlong online program offers 17 new and engaging, multiple-format CME/CE courses that are released continuously throughout the year. The state-of-the-science curriculum, developed by prominent hepatology experts, will offer clarity and guidance to clinicians on key issues and practice challenges, such as: |
- Methodology for screening and diagnosing HBV
- Prevention strategies (eg, early vaccination, screening during pregnancy)
- Optimal management strategies (including who and when to treat, and issues with long-term therapy)
- Cultural differences in patient communications
|
|
Click the "View Curriculum" button below to access the courses. Curricula III and IV can also be accessed using the search filter on the curriculum page.
|
|
|
Co-Chairs: |
|
|
Adrian M. Di Bisceglie, MD, FACP
Chairman, Internal Medicine
Chief of Hepatology
Saint Louis University
School of Medicine
St. Louis, Missouri
|
| |
|
|
Robert G. Gish, MD
Medical Director
Liver Transplant Program
Chief, Division of Hepatology and Complex GI
California Pacific Medical Center
San Francisco, California
|
| |
|
Learning Objectives:
- Assess screening, diagnosis, prevention strategies (eg, vaccination), and optimal treatment interventions of patients with or at risk of chronic HBV infection through an understanding of the epidemiology, risk factors, and disease burden imposed by HBV infection.
- Analyze cultural differences in patient communication and management of HBV infection (comparing the Asian and Pacific-Islander, Latino, black, and white communities) to bridge these differences and improve patient outcomes.
- Assess status of molecular tests in determining when to treat, optimal treatment selection and on-treatment response in chronic HBV-infected patients with diverse ethnic backgrounds to improve patient outcomes.
- Formulate anti-HBV treatment strategies, considering efficacy, therapeutic endpoints, safety, and resistance profiles of currently and emerging antiviral agents to improve response rates in culturally diverse patients with chronic HBV infection.
- Implement optimal treatment selection for special populations with chronic HBV infection to improve outcomes.
- Integrate personalized anti-HBV prescribing, treatment, and monitoring strategies to prevent, reduce, or manage drug resistance in patients with chronic HBV infection.
- Analyze barriers to initiating timely anti-HBV treatment interventions and strategies to overcome these barriers in the practice setting.
- Implement monitoring and follow-up to optimize anti-HBV therapy response for improved patient outcomes (prevent/manage drug resistance, identify/manage therapy-related side effects ensure adherence).
|
|
Projects In Knowledge poster presented
at DDW 2009
Physicians at the 2009 DDW Hepatitis B: Combined Poster Session visited Projects In Knowledge's poster, created in collaboration with Adrian Di Bisceglie, MD, FACP, and Robert Gish, MD, that addressed their proprietary survey findings and identified practice gaps clinicians want addressed in educational programs.
To access the poster PDF, click on the following link:
www.projectsinknowledge.com/DDWposter
|
In October 2008, the European Association for the Study of the Liver (EASL) published its first Clinical Practice Guidelines. The guidelines were developed to update existing guidelines for the optimal management of chronic hepatitis B.
To access the new guidelines, Click Here. |
In 2006, the Asian Pacific American Medical Student Association (APAMSA) enlisted two medical students to create a public service announcement urging the Asian Pacific American community to get screened and vaccinated for hepatitis B. The result was a spoken word performance piece that has generated widespread acclaim for its innovation and effectiveness. Click here to view this video.
|
| Covered Topics Include |
- Screening for HBV (including CDC guidelines)
- AASLD, Keeffe, and APASL Hepatitis B virus Treatment Guidelines (including updates)
- HBV virology and genotyping
- Assessing At-Risk Individuals for HBV - Special Populations
- Screening and Diagnosis in the Asian Community
- Chronic HBV Disease Burden
- HBV Treatment Options and Strategies
- HBV Treatment Resistance - Detection and Management
|
| Treatment Strategies Discussed |
- AASLD, Keeffe, and APASL HBV Treatment Guidelines
- Treatments
- Interferon and Ribavirin-based Therapy
- Oral Nucleosides/Nucleotides
- Investigational Drugs
- Combination Therapy
- Treatment Endpoints and Duration
- Monitoring for Treatment Response
|
|
Hepatitis News powered by
 |
|
|
|
|
|
About the Program
|
